Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
This study will evaluate a new critical pathway (use of guideline-based patient
identification criteria and for those who meet these criteria, use of dalbavancin) for the
treatment of ABSSSI compared to usual care.